Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics

Abstract Introduction: Patients taking second-generation antipsychotics (SGAs) are at increased risk of developing metabolic syndrome because of the side effect profiles of these medications. A medication use evaluation (MUE) was conducted and showed that baseline monitoring rates of metabolic parameters in patients taking SGAs are low. A pharmacist-run metabolic syndrome monitoring clinic (MSMC) is available to mental health (MH) outpatients; however, the clinic is underused by providers. The purpose of this project was to increase baseline metabolic syndrome monitoring rates in patients taking SGAs by implementing interventions to overcome barriers to monitoring and to accessing the MSMC. Methods: Appropriate tools to improve monitoring were obtained, and an electronic consult for the MSMC was created. A presentation and pamphlet were developed to improve awareness. Information about free patient transportation was obtained and distributed. Efficacy was assessed by evaluating patient referrals to the clinic before and after intervention, comparing baseline monitoring rates after implementation with the MUE data, and administering an anonymous survey to outpatient MH providers. Results: There was a 37.5% increase in overall referral rates to the MSMC after intervention, but only 51.5% of patients attended appointments as scheduled. Monitoring of vital signs increased, but monitoring of laboratory parameters decreased. A total of 60% (9 of 15) of providers completed a survey, of which one third indicated they still forget to refer patients to the MSMC. Discussion: Overall, baseline metabolic monitoring rates remained low despite implementing several interventions. Patient and provider outreach is crucial for initiating and maintaining a successful metabolic monitoring system for patients taking SGAs.

Download Full-text

Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics

The Canadian Journal of Psychiatry ◽

10.1177/0706743717751693 ◽

2018 ◽

Vol 63 (4) ◽

pp. 240-249 ◽

Cited By ~ 11

Author(s):

Mary Coughlin ◽

Catherine Lindsay Goldie ◽

Joan Tranmer ◽

Sarosh Khalid-Khan ◽

Deborah Tregunno

Keyword(s):

Health Care ◽

Health Care Utilization ◽

Children And Adolescents ◽

Second Generation ◽

Retrospective Chart Review ◽

Patient Treatment ◽

Care Utilization ◽

Metabolic Monitoring ◽

Second Generation Antipsychotics ◽

Outpatient Psychiatry

Objective: Children and adolescents with a range of psychiatric disorders are increasingly being prescribed atypical or second-generation antipsychotics (SGAs). While SGAs are effective at treating conduct and behavioural symptoms, they infer significant cardiometabolic risk. This study aims to explore what patient, treatment, and health care utilization variables are associated with adherence to Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) metabolic monitoring guidelines. Method: A retrospective chart review of 294 children and adolescents accessing a large outpatient psychiatry setting within a 2-year study period (2014-2016) was conducted. Baseline and follow-up metabolic monitoring, demographic, treatment, and health care utilization variables were then assessed over a 1-year period of interest. Results: Metabolic monitoring practices did not adhere to CAMESA guidelines and were very poor over the 1-year observation period. There were significant differences between children (ages 4-12 years, n = 99) and adolescents (ages 13-18 years, n = 195). In adolescents, factors associated with any baseline metabolic monitoring were a higher number of psychiatry visits (odds ratio [OR], 1.2; 95% confidence interval [CI], 1.10 to 1.41), longer duration of contact (OR, 14; 95% CI, 2.31 to 82.4), and use of other non-SGA medications (OR, 3.2; 95% CI, 1.17 to 8.94). Among children, having an emergency room visit (OR, 3.4; 95% CI, 1.01 to 11.71) and taking aripiprazole (OR, 7.4; 95% CI, 2.02 to 27.45) increased the odds of receiving baseline metabolic monitoring. Conclusion: Findings from this study highlight the need for better metabolic monitoring for children and adolescents taking SGAs. Enhanced focus on opportunities for multidisciplinary collaboration is needed to improve the quality of care offered to this population.

Download Full-text

Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics

International Journal of Mental Health Nursing ◽

10.1111/inm.12417 ◽

2017 ◽

Vol 27 (3) ◽

pp. 1188-1198 ◽

Cited By ~ 7

Author(s):

Mary Coughlin ◽

Catherine L. Goldie ◽

Deborah Tregunno ◽

Joan Tranmer ◽

Marina Kanellos-Sutton ◽

...

Keyword(s):

Children And Adolescents ◽

Second Generation ◽

Metabolic Monitoring ◽

Second Generation Antipsychotics

Download Full-text

Metabolic monitoring of psychiatric patients on second-generation antipsychotics

Annals of General Psychiatry ◽

10.1186/1744-859x-7-s1-s203 ◽

2008 ◽

Vol 7 (S1) ◽

Author(s):

Maria Markopoulou ◽

Olga Georgiadou ◽

Keranio Tsiftsoglou ◽

Konstantinos Bobotas

Keyword(s):

Second Generation ◽

Psychiatric Patients ◽

Metabolic Monitoring ◽

Second Generation Antipsychotics

Download Full-text

PHP93 ASSESSMENT OF METABOLIC MONITORING OF PATIENTS PRESCRIBED SECOND GENERATION ANTIPSYCHOTICS (SGAS) USING ELECTRONIC MEDICAL RECORD (EMR) DATA

Value in Health ◽

10.1016/s1098-3015(10)72473-6 ◽

2010 ◽

Vol 13 (3) ◽

pp. A99

Author(s):

AD Dhamane ◽

B Martin ◽

D Brixner ◽

TJ Hudson ◽

Q Said

Keyword(s):

Medical Record ◽

Electronic Medical Record ◽

Second Generation ◽

Metabolic Monitoring ◽

Second Generation Antipsychotics

Download Full-text

Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance Métabolique à Long Terme des Jeunes Traités par Antipsychotiques de Deuxième Génération, Cinq ans Après la publication des Lignes Directrices Camesa: Faisons-Nous des Progrès?

The Canadian Journal of Psychiatry ◽

10.1177/0706743720974847 ◽

2020 ◽

pp. 070674372097484

Author(s):

Sarra Jazi ◽

Leila Ben-Amor ◽

Pascale Abadie ◽

Marie-Line Menard ◽

Rachel Choquette ◽

...

Keyword(s):

Second Generation ◽

Diagnostic Category ◽

Fisher Exact Test ◽

Anthropometric Measures ◽

Psychiatric Comorbidities ◽

Mental Health Clinics ◽

Exact Test ◽

Metabolic Monitoring ◽

Second Generation Antipsychotics

Objective: The potential metabolic adverse effects of second-generation antipsychotics (SGA) need to be monitored. The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics (CAMESA) offers guidelines for this purpose. We aimed to evaluate the long-term rates of youths receiving monitoring in mental health clinics and document the factors that may influence them. Method: The charts of 180 patients (13.3 ± 3.1 years, 54.4% males) receiving SGA treatment for the first time between January 2016 and June 2018 were reviewed. Monitoring was divided into baseline and 1- to 6-month and 9- to 24-month periods. Population under study was stratified into children (4 to 12 years) and adolescents (13 to 18 years). Sociodemographic characteristics, psychiatric diagnosis and comorbidities, prescribed SGAs and comedications, anthropometric measures (AM), blood pressure (BP), blood tests (BT), electrocardiogram, and the psychiatrist’s years of practice were collected. Cross tables were used to present the monitoring rates. Categories were compared by covariate analysis. Rates of patients monitored across categories were compared using Fisher exact test. Results: Monitoring rates for AM, BT, and BP were 55%, 47.8%, and 46.7% at baseline; 50%, 41.7%, and 45.2% at 1 to 6 months; and 47.2%, 41.5%, and 40.6% at 9 to 24 months, respectively. Higher monitoring rates were significantly associated with adolescent status (baseline, 1 to 6 months), a diagnosis of psychotic and/or affective disorder (baseline, 1 to 6 months, 9 to 24 months), having ≤1 psychiatric comorbidities (1 to 6 months), high SGA dose (baseline, 1 to 6 months), and clinician’s experience (baseline, 9 to 24 months). Significantly lower monitoring rates were associated with the psychostimulant/atomoxetine comedication (baseline, 1 to 6 months, 9 to 24 months). Conclusion: Five years after publication of the CAMESA guidelines, metabolic monitoring is conducted for less than half of patients. In our sample, age, diagnostic category, psychiatric comorbidities, SGA dose, clinician’s experience, and comedications influenced the monitoring rates. Major progress still needs to be made before reaching a satisfactory level of monitoring.

Download Full-text